- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04665856
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02C)
April 11, 2024 updated by: Hoffmann-La Roche
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
123
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100142
- Beijing Cancer Hospital
-
Beijing, China, 101149
- Beijing Chest Hospital; Oncology Department
-
Bengbu City, China, 233000
- The First Affiliated Hospital of Bengbu Medical College
-
Changchun, China, 130021
- The First Hospital of Jilin University
-
Fuzhou City, China, 350014
- Fujian Provincial Cancer Hospital
-
Guangzhou, China, 510000
- Cancer Center of Guangzhou Medical University
-
Hangzhou City, China, 310022
- Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department
-
Hangzhou City, China, 310016
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
-
Harbin, China, 150081
- Harbin Medical University Cancer Hospital
-
Nanchang, China, 330019
- The 1st Affiliated Hospital of Nanchang Unversity
-
Shanghai, China, 200000
- Shanghai Chest Hospital
-
Shanghai, China, 200032
- Zhongshan Hospital Fudan University
-
Shanghai City, China, 200120
- Fudan University Shanghai Cancer Center
-
Shantou, China, 515041
- Cancer Hospital of Shantou University Medical College
-
Wuhan City, China, 430022
- Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
-
Zhengzhou, China, 450008
- Henan Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Histologically or cytologically confirmed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) per the modified Veterans Administration Lung Study Group (VALG) staging system
- No prior systemic treatment for ES-SCLC
- For participants who have received prior chemoradiotherapy for limited-stage SCLC must have had treatment with curative intent and a treatment-free interval of at least 6 months between the last dose/cycle of chemotherapy, thoracic radiotherapy, or chemoradiotherapy and the diagnosis of ES-SCLC
- Measurable diseases as defined by RECIST v1.1
- Submission of a pre-treatment tumor tissue sample
- Adequate hematologic and end-organ function
- Participants not receiving therapeutic anticoagulation with International Normalized Ratio (INR) and Activated Clotting Time (aPTT) </= 1.5 x ULN
- Participants receiving therapeutic anticoagulation: stable anticoagulant regimen
- Negative Human Immunodeficiency Virus (HIV) test at screening
- Negative hepatitis B surface antigen (HBsAg) test at screening
- Positive hepatitis B surface antibody (HBsAb) test at screening, or negative HBsAb at screening accompanied by either of the following: negative total hepatitis B core antibody (HBcAb) and/or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test
- Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test
- Negative Epstein-Barr virus (EBV) viral capsid antigen (VCA) IgM test or negative EBV polymerase chain reaction (PCR) test at screening
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm.
Exclusion Criteria:
- Symptomatic or actively progressing central nervous system (CNS) metastases
- Spinal cord compression
- Leptomeningeal disease
- Uncontrolled pleural effusion, pericardial effusion, or ascites
- Uncontrolled or symptomatic hypercalcemia
- Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease, or current alcohol abuse
- Malignancies other than SCLC within 5 years prior to randomization
- Active or history of autoimmune disease or immune deficiencies
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computer Tomography (CT) scan
- Known active tuberculosis, Current treatment with anti-viral therapy for HBV or HCV
- Severe chronic or active infection
- Treatment with therapeutic oral or IV antibiotics
- Significant cardiovascular disease
- Major surgical procedure other than for diagnosis
- Prior allogeneic bone marrow transplantation or solid organ transplant
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition
- Administration of a live, attenuated vaccine
- Prior treatment with CD137 agonists, T-cell co-stimulating, or immune checkpoint blockade therapies
- Treatment with systemic immunostimulatory agents
- Treatment with systemic immunosuppressive medications
- History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
- Known hypersensitivity to Chinese Hamster Ovary (CHO) cell products or to any component of the tiragolumab or atezolizumab formulations
- History of allergic reactions to carboplatin or etoposide
- Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab or within 90 days after the final dose of tiragolumab or for 6 months after the final dose of carboplatin or etoposide.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tiragolumab + Atezolizumab + Carboplatin and Etoposide
Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles.
Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.
|
Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Other Names:
Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Other Names:
Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
Etoposide 100 mg/m^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
|
Placebo Comparator: Placebo + Atezolizumab + Carboplatin and Etoposide
Induction treatment with placebo plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles.
Following the induction phase, participants will continue maintenance therapy with placebo plus atezolizumab for 21-day cycles
|
Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Other Names:
Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
Etoposide 100 mg/m^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set (PAS)
Time Frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 49 months)
|
From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 49 months)
|
Overall Survival (OS) in the PAS
Time Frame: From randomization to death from any cause (up to approximately 49 months)
|
From randomization to death from any cause (up to approximately 49 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PFS in the Full Analysis Set (FAS)
Time Frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 49 months)
|
From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 49 months)
|
OS in the FAS
Time Frame: From randomization to death from any cause (up to approximately 49 months)
|
From randomization to death from any cause (up to approximately 49 months)
|
Investigator-Assessed Confirmed Objective Response Rate (ORR) in the PAS
Time Frame: From randomization up to approximately 49 months
|
From randomization up to approximately 49 months
|
Investigator-Assessed Confirmed ORR in the FAS
Time Frame: From randomization up to approximately 49 months
|
From randomization up to approximately 49 months
|
Investigator-Assessed Duration of Response (DOR) in the PAS
Time Frame: From the first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 49 months)
|
From the first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 49 months)
|
Investigator-Assessed DOR in the FAS
Time Frame: From the first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 49 months)
|
From the first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 49 months)
|
Investigator-Assessed PFS Rates at 6 Months and 12 Months in the PAS
Time Frame: Month 6, Month 12
|
Month 6, Month 12
|
Investigator-Assessed PFS Rates at 6 Months and 12 Months in the FAS
Time Frame: Month 6, Month 12
|
Month 6, Month 12
|
Overall Survival Rates at 12 Months and 24 Months in the PAS
Time Frame: Month 12, Month 24
|
Month 12, Month 24
|
Overall Survival Rates at 12 Months and 24 Months in the FAS
Time Frame: Month 12, Month 24
|
Month 12, Month 24
|
Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Score in the PAS
Time Frame: Up to approximately 49 months
|
Up to approximately 49 months
|
TTCD Assessed Using EORTC QLQ-C30 Score in the FAS
Time Frame: Up to approximately 49 months
|
Up to approximately 49 months
|
Percentage of Participants with Adverse Events, Determined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
Time Frame: Up to approximately 49 months
|
Up to approximately 49 months
|
Serum Concentration of Tiragolumab at Specified Timepoints
Time Frame: Cycle 1 (each cycle=21 days), Day 1: predose, 0.5 hour (h) postdose; Cycles 2, 3, 4, 8, 12, 16, Day 1: predose and at treatment discontinuation (TD) visit (up to approximately 49 months)
|
Cycle 1 (each cycle=21 days), Day 1: predose, 0.5 hour (h) postdose; Cycles 2, 3, 4, 8, 12, 16, Day 1: predose and at treatment discontinuation (TD) visit (up to approximately 49 months)
|
Serum Concentration of Atezolizumab at Specified Timepoints
Time Frame: Cycle 1 (each cycle=21 days), Day 1: predose, 0.5 hour (h) postdose; Cycles 2, 3, 4, 8, 12, 16, Day 1: predose and at TD visit (up to approximately 49 months)
|
Cycle 1 (each cycle=21 days), Day 1: predose, 0.5 hour (h) postdose; Cycles 2, 3, 4, 8, 12, 16, Day 1: predose and at TD visit (up to approximately 49 months)
|
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab
Time Frame: Predose on Day 1 of Cycles (each cycle=21 days) 1, 2, 3, 4, 8, 12, 16 and at TD visit (up to approximately 49 months)
|
Predose on Day 1 of Cycles (each cycle=21 days) 1, 2, 3, 4, 8, 12, 16 and at TD visit (up to approximately 49 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 22, 2020
Primary Completion (Actual)
August 31, 2023
Study Completion (Estimated)
April 15, 2025
Study Registration Dates
First Submitted
December 7, 2020
First Submitted That Met QC Criteria
December 7, 2020
First Posted (Actual)
December 14, 2020
Study Record Updates
Last Update Posted (Actual)
April 12, 2024
Last Update Submitted That Met QC Criteria
April 11, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Carboplatin
- Etoposide
- Atezolizumab
Other Study ID Numbers
- YO42373
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org).
Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Carcinoma
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Lung Small Cell CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck...SuspendedExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell CarcinomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Lung Small Cell CarcinomaUnited States, Canada, Korea, Republic of, Mexico
Clinical Trials on Tiragolumab
-
Yonsei UniversityNot yet recruitingNon-small Cell Lung CancerKorea, Republic of
-
Alain AlgaziGenentech, Inc.RecruitingCarcinoma | Cancer | Head and Neck Cancer | Squamous Cell CarcinomaUnited States
-
Hoffmann-La RocheActive, not recruitingEsophageal Squamous Cell CarcinomaUnited States, France, Spain, Australia, Korea, Republic of, Argentina, Belgium, China, Portugal, Taiwan, Japan, Germany, Poland, Thailand, United Kingdom, Switzerland, Turkey, Russian Federation, Morocco, Greece, Italy, New Zealand, South Africa and more
-
Hoffmann-La RocheActive, not recruitingNon-small Cell Lung Cancer (NSCLC)United States, Belgium, Korea, Republic of, Canada, China, Denmark, Spain, Thailand, United Kingdom, Taiwan, Brazil, Germany, Mexico, Italy, Switzerland, Hong Kong, Japan, France, Turkey, New Zealand, Kenya, Poland
-
Hoffmann-La RocheActive, not recruitingEsophageal CancerKorea, Republic of, China, Hong Kong, Thailand, Taiwan
-
Hoffmann-La RocheRecruitingUrothelial CancerKorea, Republic of, United States, Brazil, China, France, Germany, Mexico, Poland, Denmark, Turkey, Australia, Greece, Spain, United Kingdom, Italy
-
M.D. Anderson Cancer CenterRecruitingMetastatic MalignancyUnited States
-
Alliance Foundation Trials, LLC.Genentech, Inc.Recruiting
-
University Medical Center GroningenRecruitingMelanoma | Head and Neck Neoplasms | MSI-H CancerNetherlands